<?xml version='1.0' encoding='utf-8'?>
<document id="28067828"><sentence text="Pharmacogenetic Foundations of Therapeutic Efficacy and Adverse Events of Statins." /><sentence text="In the era of precision medicine, more attention is paid to the search for predictive markers of treatment efficacy and tolerability" /><sentence text=" Statins are one of the classes of drugs that could benefit from this approach because of their wide use and their incidence of adverse events" /><sentence text="" /><sentence text="Literature from PubMed databases and bibliography from retrieved publications have been analyzed according to terms such as statins, pharmacogenetics, epigenetics, toxicity and drug-drug interaction, among others" /><sentence text=" The search was performed until 1 October 2016 for articles published in English language" /><sentence text="" /><sentence text="Several technical and methodological approaches have been adopted, including candidate gene and next generation sequencing (NGS) analyses, the latter being more robust and reliable" /><sentence text=" Among genes identified as possible predictive factors associated with statins toxicity, cytochrome P450 isoforms, transmembrane transporters and mitochondrial enzymes are the best characterized" /><sentence text=" Finally, the solute carrier organic anion transporter family member 1B1 (SLCO1B1) transporter seems to be the best target for future studies" /><sentence text=" Moreover, drug-drug interactions need to be considered for the best approach to personalized treatment" /><sentence text="" /><sentence text="Pharmacogenetics of statins includes several possible genes and their polymorphisms, but muscular toxicities seem better related to SLCO1B1 variant alleles" /><sentence text=" Their analysis in the general population of patients taking statins could improve treatment adherence and efficacy; however, the cost-efficacy ratio should be carefully evaluated" /><sentence text="" /></document>